Lifestance Health Valuation Analysis
| LFST Stock | USD 7.69 -0.01 -0.13% |
Below Model Estimate
Today
The intrinsic value estimate for Lifestance Health is based on a 3 months horizon. Lack of a positive P/E ratio suggests inconsistent earnings, which introduces uncertainty into valuation. Extending the time horizon generally improves valuation stability.
No single method fully captures Lifestance Health's value — the signal improves when multiple approaches converge. Mature cash-generative businesses are best valued on earnings multiples; high-growth firms may require DCF approaches.
Main Profitability Drivers
Lifestance Health converts revenue at a 0.71% net margin rate, while its operating margin sits at 1.90%. Below the operating line, items like interest and taxes compress Lifestance Health's margin by about 1.19 percentage points. Revenue of $1.42 billion translated into $487.24 million of gross profit for Lifestance Health, with net income reaching $9.66 million. The company produces 0.67% on shareholders' equity and 0.46% on total assets, framing Lifestance Health's capital efficiency picture. Lifestance Health is showing encouraging profitability momentum, even though present margin levels remain narrow rather than comfortably strong. The full picture is available through Lifestance Health's complete profitability review to assess how these metrics compare over time.
Price Book 2.02 | Gross Profit | Price Sales 2 | Profit Margin | Enterprise Value Revenue 2.17 |
Lifestance Health Cash | $261.07 million |
Cash stood at $248.64 million as of December 31, 2025.
Lifestance Health is a medical equipment provider generating revenue through device sales, innovation, and healthcare demand, which directly shapes its valuation profile and margin structure. Trading as a diversified stock in Health Care Equipment & Supplies, it shows a balanced mix of valuation characteristics in its current profile. The sections below test current market pricing against capital structure, margins, and earnings trajectory.
Total Value Analysis
The current total-value analysis for Lifestance Health Group points to enterprise value near 3.25 billion, market capitalization around 2.98 billion, debt of 194.1 million, and cash and liquid equivalents of 96.69 million as of latest reporting. Enterprise value captures what an acquirer would pay for the operating business, making it more useful than market cap alone when debt is material.| Takeover Price | Market Cap | Debt Obligations | Cash & Equivalents |
3.25 billion | 2.98 billion | 194.1 million | 96.69 million |
Investor Information
About 94.0% of LFST shares are owned by institutional investors. The book value of LFST was now reported as 3.81. LFST had not issued any dividends in recent years. Lifestance Health demonstrates moderate financial flexibility with thin profitability across liquidity and leverage indicators. Return on assets remains in positive territory, consistent with the company's business model and scale.Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lifestance Health has an asset utilization ratio of 64.62 percent. This implies that the Company is making $0.65 for each dollar of assets. An increasing asset utilization means that Lifestance Health Group is more efficient with each dollar of assets it utilizes for everyday operations.Macro event markers
Discounted Cash Flow Analysis
The current custom levered DCF for Lifestance Health suggests fair value near 7.68 per share, broadly in line with the stock price of 7.70. The market and model are not far apart on these assumptions. The setup uses a WACC of 9.43% and a long-term growth rate of 2.0%, with next-period free cash flow around 268.03 Million. Discounted forecast cash flows sum to about 648.89 Million before the terminal component, and present terminal value still represents roughly 78.0% of enterprise value.Model Value / Share
7.68
Equity value per share from the current custom levered DCF summary row.
Market Price
7.70
Current market price used by the same scenario.
Model Premium
0.3%
Market price sits above the model output.
WACC / LT Growth
9.43% / 2.0%
Forecast horizon: 2021 to 2030Terminal value share of EV: 78.0%
Lifestance Market Price vs. Intrinsic Value
This chart compares observed market pricing with the model-derived equity value per share across forecast periods. It also illustrates the relative premium or discount, expressed as a percentage difference between market valuation and modeled intrinsic value.
Projected Revenue and Levered Free Cash Flow
Revenue and levered free cash flow projections are presented in billions, outlining the expected financial trajectory over the modeled horizon.
Key Model Assumptions
The inputs below reflect the core assumptions applied in the valuation model, including growth expectations, discount rates, and capital structure considerations.
| Input | Current Value |
|---|---|
| Weighted Average Cost of Capital | 9.43% |
| Long-Term Growth Rate | 2.0% |
| Cost of Equity | 9.68% |
| After-Tax Cost of Debt | 4.70% |
| Debt Weighting | 6.06% |
| Equity Weighting | 93.94% |
| Net Debt | -54.55 million |
| Enterprise Value | 2.95 billion |
| Present Terminal Value | 2.3 billion |
| Terminal Value Share of EV | 78.0% |
Forecast Detail and Valuation Progression
This table presents the underlying forecast data used in the valuation, including revenue, cash flow generation, discounting effects, and the resulting per-share value across each projected period.
| Year | Revenue | Revenue Growth | Free Cash Flow | PV of LFCF | Equity Value / Share |
|---|---|---|---|---|---|
| 2021 | 667.51 million | 0.00% | -85.07 million | 0 | 7.68 |
| 2022 | 859.54 million | 28.77% | -26.47 million | 0 | 7.68 |
| 2023 | 1.06 billion | 22.82% | -57.4 million | 0 | 7.68 |
| 2024 | 1.25 billion | 18.50% | 85.69 million | 0 | 7.67 |
| 2025 | 1.42 billion | 13.85% | 110.03 million | 0 | 7.69 |
| 2026 | 1.58 billion | 10.90% | 92.71 million | 84.72 million | 7.68 |
| 2027 | 1.71 billion | 8.57% | 132.6 million | 110.74 million | 7.68 |
| 2028 | 1.83 billion | 6.74% | 174.91 million | 133.49 million | 7.68 |
| 2029 | 1.93 billion | 5.30% | 218.59 million | 152.45 million | 7.68 |
| 2030 | 2.01 billion | 4.17% | 262.77 million | 167.48 million | 7.68 |
Profitability Analysis
Based on the profitability measurements from Lifestance Health's financial statements, Lifestance Health Group is marginally profitable with a thin net margin of 0.71% and operating margin of 1.9%, leaving limited cushion against cost increases or revenue softness. Return on equity is 0.67%. Profitability trends are broadly favorable, with a majority of key metrics improving year over year.Net Income | First Reported 2020-03-31 | Previous Quarter 11.67 million | Current Value 14.24 million | Quarterly Volatility 36.08 million |
Macro event markers
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 33.00% | 28.53% |
|
|
Profitability for Lifestance Health depends on margin structure, capital efficiency, and cost control. Net margin of 0.71% is thin, leaving limited cushion against cost increases or revenue softness. Margin trends and return metrics below indicate whether the earnings profile is strengthening or deteriorating. Lifestance Health reports return on equity of 0.67%, positive but not at levels that signal strong capital efficiency.
Earnings per Share Projection vs Actual
Lifestance Health's forward EPS estimates provide a structured view of expected profitability based on current analyst coverage. Lifestance Health generates 1.42 billion in revenue, establishing the scale over which earnings per share are distributed. Projected earnings per share for Lifestance Health Group anchor the market's pricing of near-term earnings power. Consensus estimates may not capture non-recurring items or stock-compensation effects, so testing against the current net margin profile (0.71%), guidance revisions, and prior forecast error adds precision. Lifestance Health reported estimated earnings of 0.0844 in earnings per share on 30th of June 2026. When actual results deviate from this estimate, the gap typically signals whether earnings momentum is accelerating or fading.Macro event markers
Ownership Allocation
The majority of Lifestance Health's outstanding shares are owned by institutional investors. Institutional investors such as pension funds, mutual funds, and asset managers typically hold large positions as part of their investment mandates, managing money on behalf of clients or beneficiaries. As a result, they are subject to reporting requirements and oversight rules - such as 13F filings and position disclosure thresholds - that do not apply to individual retail investors.Revenue and Profit Overview
LFST reported previous year's revenue of $1.42 billion. Net Income was $9.66 million with profit before overhead, payroll, taxes, and interest of $487.24 million.Interpreting Recent Signals
At 0.71%, Lifestance Health has limited margin for error, amplifying the impact of any negative operating developments. Lifestance Health carries minimal debt at 0.13, more financial cushion than many comparable companies - relevant during periods of heightened market volatility. The 0.67% ROE places Lifestance Health in a range where the business covers its cost of capital but has room to improve how effectively equity translates into earnings.
Overall Interpretation
Across the key valuation dimensions, Lifestance Health Group presents a lower-margin business where revenue scale and cost control are critical to value creation within Health Care Equipment & Supplies. Positive but modest profitability reflects a competitive operating environment where incremental efficiency gains carry outsized importance. Until Lifestance Health can demonstrate sustained improvement in forward earnings expectations and sector dynamics, the market is likely to continue discounting the stock relative to peers with more established earnings power.
Valuation Framework, Methodology & Assumptions
Lifestance Health is a mid-cap equity in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care categories. Balance-sheet flexibility supports valuation resilience. For Lifestance Health, P/S of 2.0, enterprise value (TTM) of 3.25 billion, P/B of 2.02 anchors the current valuation read.
Lifestance Health Group data is compiled from periodic company reporting and market reference feeds and standardized for comparability. Valuation outputs are model-derived and depend on published assumptions and reference inputs.
The analysis above is generated by quantitative models and is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an endorsement to buy or sell any security. All investing involves risk, including the possible loss of principal. Consult a qualified financial advisor before making investment decisions. See our Terms of Use for full details.
Financial data referenced in this analysis is derived from publicly available SEC filings, audited financial statements, and third-party market data providers. The intrinsic value estimate is generated by Macroaxis quantitative models that incorporate fundamental analysis, technical indicators, and risk metrics.
The methodology combines multiple analytical inputs:
- Fundamental analysis - financial statements, profitability ratios, debt structure, and cash flow metrics sourced from SEC filings and public financial reports
- Technical indicators - historical price patterns, momentum signals, and volatility measures
- Risk assessment - probability of bankruptcy models, market risk metrics, and downside scenario analysis
- Peer comparison - relative valuation against industry peers using standardized multiples
Model outputs are refreshed periodically as new financial data becomes available. Past model performance is not indicative of future results. The intrinsic value estimate reflects a point-in-time calculation and should be considered alongside other research and professional advice.
Data sourced from SEC filings (EDGAR), public financial statements, and market data providers.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board
Growth Indicators
Growth-focused analysis of Lifestance Health Group matters because high expectations can support outsized upside but also sharper repricing when execution slips. A complete growth assessment compares growth rates with margins, cash generation, and the cost of sustaining that expansion.
| Common Stock Shares Outstanding | 391.14 million | |
| Quarterly Earnings Growth Y O Y | 19.27% | |
| Forward Price Earnings | 76.9231 |
Lifestance Health Current Valuation Indicators
A net-worth review of Lifestance Health Group links market cap to balance-sheet health, cash flow, and implied growth expectations. Earnings multiples, cash-flow yields, and asset-based measures work best as a group rather than in isolation. Reported values are derived from company filings, audited financial statements, and market data, and are standardized within Macroaxis quantitative models for consistency. Model outputs reflect a point-in-time estimate based on available data and assumptions and should be interpreted alongside changes in operating performance, market conditions, and forward expectations.
Additional Tools for Lifestance Stock Analysis
Competition AnalyzerCompare fundamental indicators side by side for a group of related or unrelated entitiesUSA ETFsFind actively traded Exchange Traded Funds (ETF) in USAETFsFind actively traded Exchange Traded Funds (ETF) from around the worldTheme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performanceETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investmentsPortfolio CenterAll portfolio management and optimization tools to improve performance of your portfoliosCryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrencyPremium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scopePositions RatingsView algorithmic ratings for individual portfolio positions based on fundamental analysis and risk-adjusted market performance